Dr. Mark M. Zalupski
Claim this profileUniversity of Michigan Comprehensive Cancer Center
Studies Gastrointestinal Tumors
Studies Adenocarcinoma
5 reported clinical trials
16 drugs studied
Area of expertise
1Gastrointestinal Tumors
ERK 1/2 positive
MEK 1/2 positive
NRAS positive
2Adenocarcinoma
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Mark M. Zalupski is currently running
Pre- and Post-Surgery Chemotherapy
for Gallbladder Cancer
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Recruiting1 award Phase 2 & 315 criteria
Ramucirumab + Chemotherapy
for Small Bowel Cancer
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium, fluorouracil, and irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced or refractory small bowel cancers and may help patients live longer.
Recruiting1 award Phase 217 criteria
More about Mark M. Zalupski
Clinical Trial Related7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mark M. Zalupski has experience with
- Ulixertinib
- Hydroxychloroquine
- Ramucirumab
- Irinotecan Hydrochloride
- Fluorouracil
- Irinotecan
Breakdown of trials Mark M. Zalupski has run
Gastrointestinal Tumors
Adenocarcinoma
Pancreatic Neuroendocrine Tumors
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark M. Zalupski specialize in?
Mark M. Zalupski focuses on Gastrointestinal Tumors and Adenocarcinoma. In particular, much of their work with Gastrointestinal Tumors has involved ERK 1/2 positive patients, or patients who are MEK 1/2 positive.
Is Mark M. Zalupski currently recruiting for clinical trials?
Yes, Mark M. Zalupski is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Mark M. Zalupski has studied deeply?
Yes, Mark M. Zalupski has studied treatments such as Ulixertinib, Hydroxychloroquine, Ramucirumab.
What is the best way to schedule an appointment with Mark M. Zalupski?
Apply for one of the trials that Mark M. Zalupski is conducting.
What is the office address of Mark M. Zalupski?
The office of Mark M. Zalupski is located at: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.